Experimental studies in genetically modified mice for IL17A or its receptor and studies using neutralizing antibodies against IL-17A further support a role for this cytokine in the pathogenesis of hypertension and associated renal and vascular end-organ dysfunction (Madhur et al., 2010; Nguyen et al., 2013; Saleh et al., 2016; Guzik and Touyz, 2017). Here, IL17A is linked to hypertensive disorder.